KALV KalVista Pharmaceuticals, Inc. Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
News✓
Loading...
All directions✓
▲ Long✓
▼ Short✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
11:36
Apr 29
A May MD Biotech investor
Chiesi announced acquisition of KALV at $27/share this morning, representing a positive fundamental event for shareholders.
KALV
MED
11:15
Apr 29
seedy19tron Biotech trader, L/S
Reacts positively to Chiesi acquiring KALV at $27/share, M&A event.
KALV
LOW

About KALV Analyst Coverage

Buzzberg tracks KALV (KalVista Pharmaceuticals, Inc.) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 2 total trade ideas tracked.